Activity Description and Educational Objectives

In this activity, renal cell carcinoma (RCC) experts discuss perspectives on recent clinical trends and guide adoption of a more nuanced and personalized approach to selecting and sequencing the available treatment options through the advanced RCC continuum. Illustrative cases detail therapeutic decision points based on patient and disease characteristics and are paired with analysis of the latest evidence on disease management and application of key clinical concepts to practice.

Upon completion of this activity, participants should be better able to:

• Discuss the latest evidence with novel approaches, including new targeted agents, immunotherapies, and combination therapies, in advanced renal cell carcinoma (RCC)
• Employ available targeted therapy and immunotherapy options effectively for patients with advanced RCC that reflect optimal patient-centric selection and sequencing through multiple lines of therapy and appropriate management of treatment-related complications
• Recommend ongoing clinical trials assessing the latest therapies and/or combination approaches for advanced RCC patients in different disease settings

Target Audience

This activity has been designed to meet the educational needs of medical and urologic oncologists and other clinicians involved in the management of patients with RCC.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: March 22, 2018 - March 21, 2019
Time to Complete: 90 minutes

Faculty & Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME activity during the past 12 months.

Course Director and Moderator

David F. McDermott, MD
Director, Biologic Therapy and Cutaneous Oncology Programs
Beth Israel Deaconess Medical Center
Leader, Dana-Farber Harvard Cancer Center Kidney Cancer Program
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

David F. McDermott, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Array BioPharma.; Bristol-Myers Squibb Company; Eisai Inc.; Exelixis, Inc.; Genentech, Inc.; Merck Sharp & Dohme Corp.; Novartis Pharmaceuticals Corporation; and Pfizer Inc.
Grant/Research Support from Prometheus Laboratories.
David F. McDermott, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: Various combination strategies with targeted agents and immunotherapies for renal cell carcinoma.

Faculty

Walter M. Stadler, MD, FACP
Fred C. Buffett Professor of Medicine & Surgery
Chief, Section Hematology/Oncology
Department of Medicine
University of Chicago
Chicago, Illinois

Walter M. Stadler, MD, FACP, has a financial interest/relationship or affiliation in the form of:
Consultant for Bristol-Myers Squibb Company; CVS Caremark; Genentech, Inc.; and Pfizer Inc.
Other Financial or Material Support: Data Safety Monitoring Board for AstraZeneca; Bayer Corporation; Eisai Inc.; and Sotio, LLC. Editorial activities for American Cancer Society and UpToDate Inc.
Walter M. Stadler, MD, FACP, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: Various combination strategies with targeted agents and immunotherapies for renal cell carcinoma.

Sumanta Kumar Pal, MD
Associate Clinical Professor, Genitourinary Malignancies
Department of Medical Oncology & Therapeutics Research
Co-director, Kidney Cancer Program
City of Hope
Duarte, California

Sumanta Kumar Pal, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Bayer Corporation; Bristol-Myers Squibb; and Genentech, Inc.
Advisory Board for AstraZeneca; Bayer Corporation; Bristol-Myers Squibb; CytomX Therapeutics, Inc.; Eisai Inc.; Exelixis, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; and Novartis Pharmaceuticals Corporation.
Sumanta Kumar Pal, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: Various combination strategies with targeted agents and immunotherapies for renal cell carcinoma.

CME Reviewer

Amer Assal, MD
Columbia University Medical Center
Blood and Marrow Transplantation Program
New York, New York

Amer Assal, MD, has no financial interests/relationships or affiliations in relation to this activity.

Medical Director

Aarati Ranganathan, PhD
PVI, PeerView Institute for Medical Education

Aarati Ranganathan, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit & Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Providership

This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This educational activity is supported by a medical education grant from Exelixis, Inc.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

Copyright © 2000-2018, PeerView